Topic: Policy

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • Evaluating Industry’s Drug Pricing Claims

  • Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy

  • Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle

  • After 4 Years of Trump, Medicare and Medicaid Badly Need Attention

  • CMS’s Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs

  • The Drugs at the Heart of Our Pricing Crisis

  • Biosimilars: Market Changes do not equal policy success

  • Bottom-Up Pricing Estimate for P-quad

  • Modeling P-quad